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INTRODUCTION
iabetes mellitus is considered to be a major health problem worldwide, [1] with 387 million people having diabetes worldwide, which is expected to rise to 592 million by 2035. In fact, diabetes is not only a condition with an increasing prevalence, but it is also a serious health problem. The International Diabetes Federation (IDF) published that diabetes led to approximately five million deaths in 2015. [2] Moreover, the [6] Major studies around this topic, such as ACCORD trial, [9] ADVANCE trial, [10] and VADT, [11] have failed to show that lowering HbA1c levels can reduce the incidence of macrovascular adverse effects. However, the ACCORD trial was stopped prematurely due to high mortality rate; [12] therefore, their results cannot be considered. The VADT was a small study with a predominantly male sample (only three females were recruited), meaning it was not representative of the general population; in addition, male gender is considered as an independent risk factor for CVDs.
[4]
Furthermore, the UK Prospective Diabetes Study (UKPDS) showed a statistically insignificant reduction in the CV endpoints after an intervention period of ten years.
[13]
Surprisingly, the 10-year follow-up of UKPDS (UKPDS 80) showed that there was a statistically significant reduction in the incidence of myocardial infarction ten years after the intervention period had ended. [14] However, an argument against this emerging benefit is that the growing number of events in both groups over this long period may have contributed to the change in analysis. As results from major studies about the benefit of reducing HbA1c on cardiovascular outcomes are variable, it raises the question about whether the HbA1C level is related to the development of macro vascular complication. In fact, atherosclerosis is the underlying disease process that leads to coronary artery disease, stroke, and peripheral artery disease. Atherosclerosis is a condition in which the fatty plaques where deposited inside the arteries.
[15] A well accepted non-invasive indicator of the development of the early stages of atherosclerosis (subclinical atherosclerosis (SCA)) is the measurement of carotid intima-media thickness (CIMT), which is calculated by using high-resolution B-mode ultrasonography.
[16] Therefore, and for a better understanding of the association between glycemic control and macrovascular complications, several epidemiological studies have investigated the correlation between HbA1c levels, as a marker of glycemic control, and CIMT measurements, as a predictor of SCA, which is the underlying process in the pathophysiology of macrovascular complications. Some of these studies have investigated this association in Asian populations (17-22), while others have done so in western populations (23-25). However, results from these studies showed conflicting findings, with some determining a positive correlation between HbA1c and CIMT, and others being unable to confirm this association.
The aim of the study: the aim of this study is to clarify the correlation between HbA1c levels and CIMT measurements in patients with T2DM and to determine other risk factors for cardiovascular disease, including lipids, blood pressure, smoking, obesity, male gender, and increasing age.
PATIENTS AND METHODS

Study Design and Population:
The study protocol had been approved by the scientific committee of the department of internal medicine and the ethical committee of College of Medicine, University of Basrah. All methods were carried out in accordance with guidelines and regulations followed at the College of Medicine and its Teaching Hospital (AL-Sadder Teaching Hospital). A crosssectional observational study was conducted to answer the research question on the correlation between HbA1c levels and CIMT measurements. [26] From March 2016 to September 2016, a total of 111 patients were collected from AL-Sadder Teaching Hospital in Basrah city. All of them were outpatients. Patients included in this study were known cases of T2DM, and had no atherosclerotic cardiovascular disease (ASCVD), namely, ischemic heart disease or cerebral vascular accident. Forty patients were excluded because they had one or more of the exclusion criteria listed below. The study exclusion criteria were categorized as factors that may have influenced the accuracy of the HbA1c readings (27-28) and factors that may have affected the development of SCA. The former criteria are if a patient had one or more of the following conditions: The use of statin belonged to the second category, as this may prevent or delay the development of SCA if taken at an appropriate dose.
[29] Also the patients with history of ASCVD were excluded.
Ethics and Consent
Informed consent was obtained from all patients, and their identities remained anonymous during the entire study process. 
Clinical Evaluation and Anthropometric Measurements
Blood Collection and Biochemical Parameters
Random blood samples were drawn for total cholesterol (TC), triglycerides (TG), and HbA1c assays. According to HbA1c level, the patients were divided into those with HbA1C level ≤ 9% and those with HbA1c > 9%. We used 9% value of HbA1c as a cut-off point as glycemic control is considered to be poor if HbA1c value is more than 9%.
[4] Lipid profile and HbA1c were measured using an automated biochemical instrument (Cobas Integra 400, Roche, Germany). The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA)
Measurement of Carotid Intima-Media Thickness
A certified investigator examined common carotid arteries (CCAs) bilaterally by a B-mode ultrasound, using a high-resolution instrument (SonoSite Inc., Bothell, WA 98021 USA). Ultrasound measurements were performed according to Mannheim CIMT Consensus.
[32]
CIMT was measured on both CCAs, at a point located approximately 20 millimetres from the bulb. Three measurements were obtained from different sites of this segment, and the mean value of six measurements (of both sides) was used for analysis. A value up to 0.9 mm was accepted as a normal value of CIMT according to the European Society of Cardiology/ European Society of Hypertension guidelines, [33] published in 2013. According to CIMT values, participants were divided into two groups: a normal CIMT value of ≤ 0.9 mm group, and a CIMT value of > 0.9 mm group, before collected variables were compared between the two.
Statistical Analysis
The statistical analysis of collected data used descriptive analysis in addition to an analytic approach to determine the relationship between the study output index (CIMT and the demographic, and predictor variables included in the study). Descriptive analysis includes determining the frequency (in tables) and pictorial presentation (bar charts, histograms, and pie charts). Continuous data is expressed as a mean with standard deviation, while categorical data is expressed as a frequency. Analytical tests used the chi-square and correlation coefficient using the Statistical Package for Social Science version 20 (SPSS-20) at a significance level of 0.05.
RESULTS
A total of 71 patients were recruited in the study. The response rate was (100%). The mean age was (52.7 ± 6.42) years. The gender distribution showed that 44 patients (61.97%) were females and the remaining (38.03%) were males ( Figure-1) .
Fig 1. The gender distribution among T2DM patients (n=71)
The mean BMI was 29.55 ± 4.72 Kg/m 2 . About one-half of the patients (36 patients, 50.7%) were hypertensive, while only three patients (4.22%) were smokers. The minimum, maximum, mean and standard deviations of the measured indices of the participants are shown in (Table-1 ). 
Fig 3. Histogram distribution of HbA1c values
The percentage of increased CIMT (> 0.9 mm) in the studied samples was about 78.8% (56 subjects out of a total 71 participants), as demonstrated in (Figure-4) .
Fig 4. The percentage of increased CIMT amongst T2DM patients
There was no significant difference in CIMT measures between the two genders ( Table-2 ). When the patients were divided according to hypertension history into two groups, no significant difference in CIMT measures was found between the two groups ( Table-4) . The patients were divided according to HbA1c level into two groups; the first group includes patients with HbA1C ≤ 9%, while the second one includes patients with HbA1C > 9%. The former group included 50.70% of patients, while 49.30% belonged to the latter, as illustrated by the pie chart in Figure 5 .
Fig 5. The frequency and percentage of patients according to glycemic control
A significant difference in CIMT between these two groups was found. Thirty two patients out of thirty five with poorly controlled diabetes (HbA1c > 9%) had increased CIMT (Chisq = 6.53, P = 0.010), as shown in (Table-5 ). Correlation coefficient analysis between CIMT was nonsignificant. HbA1c correlation was 0.113 (P = 0.348), total cholesterol correlation was 0.15 (P = 0.904), TG correlation was 0.096 (P = 0.425), BMI correlation was 0.083 (P = 0.390). Interestingly, the only significant correlation found in this study was between CIMT and age, which was 0.359 (P = 0.002). Further analysis was carried out for subjects with poor glycemic control (HbA1c > 9%). The result of analysis of data belonging to this group showed a significant correlation between HbA1c levels and CIMT, with correlation coefficients of 0.409 and P value of 0.015, while other variables had no significant correlation. the subgroup analysis of data belonging to participants with poor glycemic control (HbA1c > 9%) showed a significant correlation between HbA1c levels and CIMT, with a correlation coefficient of 0.409 (P = 0.015). Indeed, several cross-sectional studies have also investigated this correlation and many published studies on western or Asian populations support our findings. The Kora 4 study was a large population-based study on a western population and recruited participants with and without diabetes.
[24] The authors concluded that the relation between HbA1c and CIMT faded after adjustment for other cardiovascular risk variables. However, the mean HbA1c of those with known diabetes in the KORA 4 study was 6.9% ± 0.9, which is lower than the mean of our population. This supports the positive correlation of our study that appeared only in the subgroup analysis of data belonging to the poor glycaemic control (HbA1c > 9%) group. Similarly, no correlation was found between these two variables in a study conducted on an elderly population by Du HW et al. in which the mean HbA1c level was also lower than that of our population (6.9 ± 1).
[22] Moreover, they recruited old age people for whom the impact of diabetes on the development of cardiovascular events was significantly smaller than a younger age group, as found by a post Hoc analysis of participants included in two studies: (the Cardiovascular Health Study and the Atherosclerosis Risk in Communities study).
[34]
Du HW et. al concluded that the presence of hypertension had a bigger impact than hyperglycaemia on the development of CIMT. Also, Olt et al. conducted their study on an Asian population with a mean HbA1c value of 8.6 ± 2, and found that there was no significant association between HbA1c levels and CIMT values.
[35] However, no effort was given to performing subgroup analysis according to glycemic control level as we did. In contrast, many studies have confirmed a significant positive correlation between high HbA1c levels and increased CIMT values. [18] [19] [20] 36] We can explain the results of the positive correlation between glycated haemoglobin and CIMT in participants with poor glycemic control can be explained via two concepts. Firstly, as HbA1c is a glycated protein and regarded as a precursor for advanced glycation end products (AGEs) (37-38), it is considered an important factor in the pathogenesis of atherosclerosis in patients with diabetes.
[39] Secondly, HbA1c is closely related to fasting plasma glucose (FPG) levels, which are caused by insulin resistance more than insulin deficiency, [40] with the former having been proven as an associated factor with atherosclerosis. [41] Consequently, increased
HbA1c may contribute to the development of CIMT through insulin resistance. However, the correlation coefficient of 0.4 found in this study is considered to be an intermediate correlation, i.e. not a strong correlation. [42] This can be explained by the fact that postprandial glucose (PPG) levels, which are not reflected by HbA1c, as well as glucose instability with peaks and troughs, are independent risk factors for atherosclerosis and macrovascular complications.
CONCLUSION AND IMPLICATIONS
This cross-sectional study revealed that HbA1c levels in patients with poor glycemic control are positively correlated with increased CIMT measures, which is an indicator of SCA. Moreover, increased age is found to be a predictor factor for the development of SCA and, consequently, adverse macrovascular outcomes in patients with T2DM. This study provided an implication for managing patients with diabetes, particularly those who are elderly, to prevent unfavourable cardiovascular outcomes. In Iraq, as a developing country, the rate of adequate glycemic control for patients with diabetes is still disappointingly low. Depending on our results, clinicians should aim to maintain HbA1c levels within normal range as a priority to avoid the development of cardiovascular events.
